RI

RIBOMIC Inc.

Develops RNA aptamer therapeutics for ophthalmology, pain, fibrosis, and other unmet medical needs.

4591 | T

Overview

Corporate Details

ISIN(s):
JP3974850004
LEI:
Country:
Japan
Address:
港区白金台3−16−13 白金台ウスイビル6階
Sector:
Mining and quarrying
Industry:
Mining of non-ferrous metal ores

Description

RIBOMIC Inc. is a clinical-stage biopharmaceutical company specializing in the discovery and development of aptamer therapeutics. The company utilizes its proprietary RiboART system, a unique platform technology, to generate first-in-class, molecularly targeted drugs using RNA aptamers. RIBOMIC's research and development pipeline focuses on addressing unmet medical needs in a range of therapeutic areas, including ophthalmic disorders, pain, fibrosis, bone diseases, and rare diseases. The company pursues its mission through internal drug development programs and strategic partnerships within the pharmaceutical industry.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-11-12 08:30
Registration Form
確認書
Japanese 8.0 KB
2025-11-12 08:30
Interim Report
半期報告書-第23期(2025/04/01-2026/03/31)
Japanese 261.6 KB
2025-07-23 08:45
Registration Form
有価証券届出書(組込方式)
Japanese 326.2 KB
2025-06-20 03:50
Registration Form
確認書
Japanese 7.9 KB
2025-06-20 03:49
Governance Information
内部統制報告書-第22期(2024/04/01-2025/03/31)
Japanese 22.3 KB
2025-06-20 03:43
Annual Report
有価証券報告書-第22期(2024/04/01-2025/03/31)
Japanese 2.0 MB
2024-11-13 02:14
Report Publication Announcement
確認書
Japanese 7.9 KB
2024-11-13 02:13
Interim Report
半期報告書-第22期(2024/04/01-2025/03/31)
Japanese 207.6 KB
2024-06-26 04:47
Post-Annual General Meeting Information
臨時報告書
Japanese 22.7 KB
2024-06-26 04:45
Governance Information
内部統制報告書-第21期(2023/04/01-2024/03/31)
Japanese 22.1 KB
2024-06-26 04:44
Registration Form
確認書
Japanese 8.0 KB
2024-06-26 04:43
Annual Report
有価証券報告書-第21期(2023/04/01-2024/03/31)
Japanese 2.0 MB
2024-02-14 02:26
Report Publication Announcement
確認書
Japanese 7.9 KB
2024-02-14 02:25
Quarterly Report
四半期報告書-第21期第3四半期(2023/10/01-2023/12/31)
Japanese 178.6 KB
2023-11-13 08:01
Report Publication Announcement
確認書
Japanese 7.9 KB

Automate Your Workflow. Get a real-time feed of all RIBOMIC Inc. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for RIBOMIC Inc.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for RIBOMIC Inc. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

ECHOMARKETING Co.,Ltd. Logo
Global agency accelerating sales with data-driven, full-funnel digital marketing.
South Korea
230360
Eezy Oyj Logo
HR services firm for the full employment lifecycle, from recruitment to freelancer support.
Finland
EEZY
Elicio Therapeutics, Inc. Logo
Develops lymph node-targeted immunotherapies for aggressive, KRAS-driven cancers.
United States of America
ELTX
enCore Energy Corp. Logo
American uranium producer using ISR technology to fuel the U.S. nuclear energy sector.
United States of America
EU
ENERGY FUELS INC Logo
A leading U.S. producer of uranium and rare earth elements for EVs, defense, and technology.
United States of America
UUUU
ENIGMATIG LTD Logo
Global expansion and regulatory compliance consultancy for the financial services industry.
United States of America
EGG
Enjin Co., Ltd. Logo
PR firm for SMEs and medical institutions, offering consulting and a media matching platform.
Japan
7370
Ensol Biosciences Inc. Logo
Develops AI-discovered peptide drugs for cancer, osteoarthritis, and Alzheimer's disease.
South Korea
140610
Enveric Biosciences, Inc. Logo
Develops novel neuroplastogen drugs for severe mental health and addiction disorders.
United States of America
ENVB
Eutilex Co.,Ltd. Logo
Develops T-cell and antibody immunotherapies for cancer and autoimmune diseases.
South Korea
263050

Talk to a Data Expert

Have a question? We'll get back to you promptly.